On Jun. 22, 2021, the National Research Council of Canada (NRC) announced it had completed construction of the new Biologics Manufacturing Centre on the Royalmount site in Montreal, Quebec.

Once fully licensed and operational, the Biologics Manufacturing Centre will provide full end-to-end manufacturing capabilities. With approximately 5,400 square metres (58,000 square feet) of space, it has a production capacity of approximately 24 million doses of a vaccine per year, varying based on the specific vaccine requirements.

The NRC is continuing to work with Novavax to produce their COVID-19 vaccine at the Biologics Manufacturing Centre once both the vaccine candidate and the facility receive Health Canada approvals.